New data from phase 3b COSMOS study of guselkumab show improvement in joint symptoms and complete skin clearance in patients with psoriatic arthritis and inadequate response to tumor necrosis factor inhibition (TNFi-IR)

In RCT (n=285), a significantly higher proportion of patients treated with this selective IL-23 inhibitor showed joint symptom improvement (44.4 vs. 19.8%) and complete skin clearance (30.8 vs. 3.8%) versus placebo at week 24.

Source:

Biospace Inc.